CEO Matthew Hawkins Executes Rapid Buy‑Sell of 82,500 Waystar Shares in Structured Plan, Leveraging $4.14 Purchase to $26.23 Sale for Quick Profit【Waystar Holding Corp.】

Insider Activity Spotlight: Waystar Holding Corp.

Recent Insider Move On October 6, 2026, Chief Executive Officer Matthew Hawkins executed a Rule 144 transaction that saw him purchase 82,500 shares of Waystar common stock at $4.14 each, immediately followed by a sale of the same quantity at $26.23. The rapid buy‑sell sequence—completed within the same filing period—suggests a structured, pre‑planned transaction, likely under a 10b‑5(b)(1)(c) rule‑based plan that locks in a sale price while preserving the ability to buy back the shares at a lower price. The timing also aligns with the company’s recent stock‑price rebound (1.74 % weekly, 6.35 % monthly), offering Hawkins the opportunity to capitalize on a price uptick while maintaining his overall equity stake.

Implications for Investors For shareholders, the move signals a short‑term confidence in the company’s valuation trajectory. By buying at $4.14 and selling at $26.23, Hawkins demonstrates that the CEO believes Waystar’s stock is worth far more than its recent intraday lows. However, the sale’s execution via a Rule 144 plan also indicates a commitment to share liquidity and transparency, potentially reducing the perception of insider speculation. Investors should note that, although the transaction is routine, it highlights the CEO’s willingness to use structured plans to manage his holdings in a volatile healthcare environment—an environment that has seen the stock drop 31.13 % year‑to‑date.

CEO Profile: A Pattern of Strategic Equity Management Hawkins has a long history of disciplined insider activity. Since early 2025, he has routinely bought and sold shares in blocks of 82,500 and 60,038, often using Rule 144 or Rule 10b‑5(b)(1)(c) plans to mitigate market impact. His activity shows a preference for buying at lower prices (e.g., $4.14 in March 2025, $4.14 in August 2025) and selling near or above the current market rate (e.g., $25.73–$26.23 in September–October 2026). Additionally, he has actively exercised stock options in large volumes (over 82,500 shares in October 2026), suggesting a strategy of converting options to cash when the price exceeds a target threshold. This pattern reflects a CEO who balances long‑term equity ownership with periodic liquidity events, a practice common among leaders of growing healthcare companies seeking to fund expansion while maintaining shareholder confidence.

Company‑Wide Insider Trends Beyond Hawkins, Waystar’s board and senior leadership have exhibited moderate insider activity. Chief Product & AI Officer William Chan recently sold a block of shares in a sell‑to‑cover transaction, while other executives have made modest purchases and sales, often tied to vesting schedules and tax‑deferral strategies. The overall insider transaction volume has remained within regulatory limits and has not disrupted the stock’s broader market dynamics, indicating that the company’s governance framework is effectively managing equity distribution among its leadership.

Looking Ahead With the stock’s 52‑week high at $40.35 and a current market cap of $5.08 billion, Waystar is positioned in a competitive healthcare landscape where strategic investments and disciplined capital allocation are key. Hawkins’ recent buy‑sell activity underscores a willingness to align personal gains with corporate performance. For investors, this signals a CEO who actively monitors market conditions and employs structured plans to maintain liquidity without compromising long‑term ownership—a prudent approach that may bode well for Waystar’s future growth prospects.